Gefitinib 250 mg Tab
| Product Overview | |
| Generic Name | Gefitinib 250 mg Tab |
| Brand Name(s) | Iressa® |
| Form | 30 Film-coated tablets (oral). |
| Strength | 250 mg tablet |
| Therapeutic Class | Tyrosine kinase inhibitor – epidermal growth factor receptor (EGFR-TKI) |
| ATC Code | L01EB01 |
| Manufacturing & Regulatory | |
| Manufacturer | AstraZeneca, Natco, Cipla |
| Country | UK, India, Mexico |
| GMP Compliance | WHO-GMP |
| Free Sale Certificate | Available per batch upon request |
| Logistics & Export | |
| MOQ | 100 units |
| Shelf Life | 24 Months |
| Storage | Store below 30°C Protect from moisture and light. Do not refrigerate or freeze. |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes—lot-specific Certificate of Analysis |
Description
Gefitinib is an orally administered, selective EGFR tyrosine-kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours harbour activating EGFR mutation
